Sugi Predict

Sugi Predict / Compounds / SCHEMBL241844

SCHEMBL241844

SCHEMBL241844

Cc1ccc(O)c(CO)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 1.00
▸ KDM4E B2RXH2 5/20 1.00
▸ HPGD P15428 4/20 0.62
▸ HSD17B10 Q99714 3/20 0.62
▸ USP2 O75604 1/20 0.62
▸ GFER P55789 1/20 0.55
▸ RAB9A P51151 3/20 0.53
▸ KMT2A Q03164 3/20 0.44
▸ OPRK1 P41145 1/20 0.44
▸ LMNA P02545 2/20 0.44
▸ HIF1A Q16665 2/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.43
▸ METAP2 P50579 1/20 0.41
▸ GRM5 P41594 2/20 0.39
▸ MEN1 O00255 2/20 0.39
▸ NPC1 O15118 1/20 0.39
▸ TP53 P04637 1/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2D6 P10635 1/20 0.39
▸ MAPT P10636 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30775071 1.00 ALDH1A1 (1.00) ALDH1A1KDM4EHPGDHSD17B10USP2
Emoxypine SCHEMBL21061700 0.84 KDM4E (0.73) ALDH1A1KDM4EHPGDHSD17B10USP2
Emoxypine SCHEMBL195347 0.84 KDM4E (0.72) ALDH1A1KDM4EHPGDHSD17B10USP2
Emoxypine SCHEMBL29362452 0.84 KDM4E (0.72) ALDH1A1KDM4EHPGDHSD17B10USP2
Emoxypine SCHEMBL1373708 0.82 KDM4E (0.69) ALDH1A1KDM4EHPGDHSD17B10USP2
Emoxypine SCHEMBL31074958 0.82 KDM4E (0.69) ALDH1A1KDM4EHPGDHSD17B10USP2
Emoxypine SCHEMBL11089142 0.82 KDM4E (0.69) ALDH1A1KDM4EHPGDHSD17B10USP2
SCHEMBL12831698 0.80 KDM4E (0.67) ALDH1A1KDM4EHPGDHSD17B10USP2
SCHEMBL9007842 0.80 KDM4E (0.67) ALDH1A1KDM4EHPGDHSD17B10USP2
SCHEMBL1237716 0.80 KDM4E (0.67) ALDH1A1KDM4EHPGDHSD17B10USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 192 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3676261-B1 SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS CHRONOS THERAPEUTICS LTD (GB) 2024-12-18 — — EP disclosed
EP-4408967-A1 BRANDY REPLICAS AVA FOOD LABS, INC. (US) 2024-08-07 — — EP disclosed
CN-111315734-B Substituted 2-azabicyclo [3.1.1] heptane and 2-azabicyclo [3.2.1] octane derivatives as orexin receptor antagonists 克罗诺斯治疗有限公司 2024-03-08 — — CN disclosed
US-20230192691-A1 HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS BEIJING INNOCARE PHARMA TECH CO LTD (CN) 2023-06-22 — — US disclosed
US-20230192691-A1 HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS BEIJING INNOCARE PHARMA TECH CO LTD (CN) 2023-06-22 — — US disclosed
US-20230192691-A1 HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS BEIJING INNOCARE PHARMA TECH CO LTD (CN) 2023-06-22 — — US disclosed
US-11660293-B2 Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists CHRONOS THERAPEUTICS LIMITED (GB) 2023-05-30 — — US disclosed
WO-2023055801-A1 BRANDY REPLICAS AVA FOOD LABS, INC. (US) 2023-04-06 — — WO disclosed
US-20220401432-A1 THERAPEUTIC METHODS, COMBINATIONS AND KITS REGENTS OF THE UNIVERSITY OF MINNESOTA 2022-12-22 — — US disclosed
US-20220331299-A1 SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS CHRONOS THERAPEUTICS LIMITED (GB) 2022-10-20 — — US disclosed
US-5290942-A Acetylcholinesterase inhibitors GEORGIA TECH RESEARCH CORPORATION (US) 1994-03-01 — — US disclosed
WO-1993024459-A1 QUATERNARY PYRIDINIUM COMPOUNDS GEORGIA TECH RESEARCH CORPORATION (US) 1993-12-09 — — WO disclosed
US-5206371-A Acetylcholinesterase inhibitor GEORGIA TECH RESEARCH CORPORATION (US) 1993-04-27 — — US disclosed
US-5180831-A Acetylcholinesterase Inhibitors GEORGIA TECH RESEARCH CORPORATION (US) 1993-01-19 — — US disclosed
EP-0472783-A1 Anti-tumor compositions and compounds PHARMACHEMIE B.V. (NL) 1992-03-04 — — EP disclosed
EP-0462800-A2 Inhibitors of HIV reverse transcriptase MERCK & CO. INC. (US) 1991-12-27 — — EP disclosed
US-4212976-A ANTIARTHRITIC AGENTS MERCK & CO., INC. (US) 1980-07-15 — — US disclosed
US-4057637-A RHEUMATOID ARTHRITIS MERCK & CO., INC. (US) 1977-11-08 — — US disclosed
US-3971797-A ANTIARTHRITIC MERCK & CO., INC. (US) 1976-07-27 — — US disclosed
US-3935224-A 4H-Pyrido[3,2a]-1,3,2-dioxophosphorane derivatives CIBA-GEIGY CORPORATION (US) 1976-01-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220401432-A1 THERAPEUTIC METHODS, COMBINATIONS AND KITS MMP8, TLR7, GOT2 ALDH1A1 465/4885KDM4E 4602/4885HPGD 511/4885
US-20220331299-A1 SUBSTITUTED 2-AZABICYCLO[3.1.1]HEPTANE AND 2-AZABICYCLO[3.2.1]OCTANE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS HCRTR2, HCRTR1, NPY1R ALDH1A1 589/4885KDM4E 2153/4885HPGD 2525/4885
US-20230192691-A1 HETEROCYCLIC COMPOUNDS AS BTK INHIBITORS BTK, SYK, LYN ALDH1A1 3975/4885KDM4E 1357/4885HPGD 3944/4885
US-11660293-B2 Substituted 2-azabicyclo[3.1.1]heptane and 2-azabicyclo[3.2.1]octane derivatives as orexin receptor antagonists HCRTR2, HCRTR1, NPY1R ALDH1A1 589/4885KDM4E 2153/4885HPGD 2525/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.